Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Shooting for 100 Billion Yen Sales in US/Europe, 50% Overseas Ratio
January 23, 2019
- Astellas to Transfer Dormicum to Maruishi
January 23, 2019
- Astellas, Kaketsuken Successor End Vaccine, Blood Product Pact
January 23, 2019
- SanBio’s Cell Therapy to Be Developed for Brain Bleeding Too
January 22, 2019
- Shionogi Upping Xofluza Production to Get Back to Normal before Flu Season Ends
January 22, 2019
- Mitsubishi Tanabe Eyes US as 1st Launch Market, Zeroes in on Immunology/CNS: Chief
January 22, 2019
- Janssen, Nippon Shinyaku to Copromote Prostate Cancer Treatment Apalutamide in Japan
January 22, 2019
- Shionogi Facing Xofluza Supply Crunch as Flu Season Gets into Full Swing
January 21, 2019
- Meiji Gets Thailand/Indonesia Rights to Toray’s Remitch
January 21, 2019
- Opdivo Wins Label Expansion for NSCLC in Taiwan: Ono
January 21, 2019
- Eisai’s Voluntary Redundancy Program Draws 300 Applicants in 1st Round, 3 Times More than Planned
January 21, 2019
- Chugai Files Gene Panel Test for Use as Companion Diagnostic to Entrectinib
January 21, 2019
- Novo to Cease Dealings with 6 Wholesalers from April to Cut Distribution Costs
January 21, 2019
- Mitsubishi Tanabe Staffers Tapping New Support System to Balance Work and Infertility, Medical Treatment
January 18, 2019
- Ethical Drug Sales Slip 0.2% in November: Crecon
January 18, 2019
- Astellas, AstraZeneca Wind Up Symbicort Collaboration
January 18, 2019
- Takeda Becomes 1st Japan Drug Maker to Ring Opening Bell at NYSE
January 16, 2019
- Daiichi Sankyo Launches PIII DS-8201 Study in HER2-Low Breast Cancer
January 16, 2019
- Beverage Maker DyDo to Enter Orphan Drug Field Aiming at “Second Pillar of Business”
January 16, 2019
- Insomnia Treatment Lemborexant Filed for US Approval: Eisai, Purdue Pharma
January 16, 2019
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…